MENA Newswire News Desk: The World Health Organization (WHO) today released a landmark study published in eBioMedicine, identifying 17 pathogens that pose significant health risks and are in urgent need of vaccine development. This extensive research is the first global initiative to systematically prioritize endemic pathogens based on a range of critical factors, including disease burden by region, risks posed by antimicrobial resistance, and the socioeconomic impact of each pathogen.
The study reaffirms the critical need for vaccine research and development (R&D) for long-standing threats such as HIV, malaria, and tuberculosis, which together account for nearly 2.5 million deaths worldwide each year. In addition to these diseases, the WHO identified several other pathogens that require immediate attention due to their increasing resistance to current antimicrobial treatments and their widespread health impact across various regions.
Among these newly prioritized pathogens are Group A Streptococcus and Klebsiella pneumoniae, both of which are listed as high priorities for vaccine development due to their association with significant morbidity and mortality and their growing resistance to available antibiotics. These pathogens, WHO states, pose a pressing challenge for disease control, necessitating innovative solutions to combat their resilience to existing treatments.
Dr. Kate O’Brien, Director of the WHO’s Immunization, Vaccines, and Biologicals Department, highlighted the importance of this data-driven approach in determining global vaccine priorities. She noted that vaccine R&D decisions have often been influenced more by potential financial returns than by the ability to save lives in vulnerable populations. “This study leverages regional expertise and comprehensive data to prioritize vaccines that could significantly reduce the burden of diseases affecting communities today, while also reducing medical expenses for families and healthcare systems,” she stated.
The WHO report also highlights other pathogens for which vaccine candidates are nearing regulatory approval or may soon receive political endorsements. These include the dengue virus, Group B Streptococcus, extra-intestinal pathogenic Escherichia coli, Mycobacterium tuberculosis, and the respiratory syncytial virus (RSV).
The establishment of this global priority list for vaccine R&D aligns with the WHO’s Immunization Agenda 2030, which aims to ensure that people worldwide have access to vaccines that protect against severe diseases. By identifying these pathogens and advocating for their vaccine development, WHO aims to drive forward an agenda that protects all communities, particularly those most at risk, and reinforces global health resilience.